Vertex Pharmaceuticals (VRTX)
| Sector: | Health Care |
| |
| Super Investor Stats: | |
| Ownership count: | 3 |
| Ownership rank: | 206 |
| % of all portfolios: | 0.041% |
| Hold Price * : | $465.06 |
| History |
Portfolio Manager |
Activity |
Share change |
% change to portfolio ▼ |
| Q3 2024 |
| ≡ |
John Armitage - Egerton Capital |
Buy |
124,045 |
0.58 |
| ≡ |
Torray Funds |
Add 13.01% |
1,813 |
0.12 |
| Q2 2024 |
| ≡ |
Tweedy Browne Co. - Tweedy Browne Value Fund |
Reduce 16.96% |
3,135 |
0.35 |
| ≡ |
Torray Funds |
Add 0.28% |
39 |
0.00 |
| Q1 2024 |
| ≡ |
Torray Funds |
Reduce 1.20% |
169 |
0.01 |
| ≡ |
Lee Ainslie - Maverick Capital |
Sell 100.00% |
812 |
0.01 |
| Q4 2023 |
| ≡ |
Torray Funds |
Buy |
14,068 |
0.93 |
| ≡ |
Lee Ainslie - Maverick Capital |
Reduce 44.27% |
645 |
0.01 |
| Q3 2023 |
| ≡ |
Tweedy Browne Co. - Tweedy Browne Value Fund |
Reduce 3.65% |
700 |
0.06 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
1,457 |
0.01 |
| Q2 2023 |
| ≡ |
Tweedy Browne Co. - Tweedy Browne Value Fund |
Reduce 19.45% |
4,635 |
0.39 |
| Q4 2021 |
| ≡ |
Tweedy Browne Co. - Tweedy Browne Value Fund |
Buy |
23,825 |
1.26 |
| ≡ |
Lee Ainslie - Maverick Capital |
Sell 100.00% |
18,052 |
0.04 |
| Q3 2021 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
18,052 |
0.04 |
| Q2 2021 |
| ≡ |
Lee Ainslie - Maverick Capital |
Sell 100.00% |
6,254 |
0.01 |
| Q1 2021 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
6,254 |
0.01 |
| Q2 2020 |
| ≡ |
Lee Ainslie - Maverick Capital |
Sell 100.00% |
460 |
0.00 |
| Q1 2020 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
460 |
0.00 |
| Q2 2015 |
| ≡ |
Lee Ainslie - Maverick Capital |
Sell 100.00% |
524,867 |
1.00 |
| Q1 2015 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
524,867 |
1.00 |
| Q2 2009 |
| ≡ |
Bill & Melinda Gates Foundation Trust |
Sell 100.00% |
95,000 |
0.03 |
| Q1 2009 |
| ≡ |
Bill & Melinda Gates Foundation Trust |
Buy |
95,000 |
0.03 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.